Background:

Avosentan(Ro 67-0565; SPP-301) is a potent, selective endothelin receptor(ETA receptor) antagonist.IC50 value:Target: ETA receptor

参考文献:
[1]. Baltatu OC, Iliescu R, Zaugg CE, Reckelhoff JF, Louie P, Schumacher C, Campos LA.Antidiuretic effects of the endothelin receptor antagonist avosentan.Front Physiol. 2012;3:103.
[2]. Konieczka K, Meyer P, Schoetzau A, Neutzner A, Mozaffarieh M, Flammer J.Effect of avosentan (SPP-301) in porcine ciliary arteries.Curr Eye Res. 2011 Feb;36(2):118-24.
[3]. Mann JF, Green D, Jamerson K, Ruilope LM, Kuranoff SJ, Littke T, Viberti G; ASCEND Study Group.J Am Soc Nephrol. 2010 Mar;21(3):527-35.
[4]. Dieterle W, Hengelage T.Absolute bioavailability and pharmacokinetics of avosentan in man.Int J Clin Pharmacol Ther. 2009 Sep;47(9):587-94.
[5]. Effect of SPP 301, an Endothelin Antagonist, on Intraocular Pressure in Glaucomatous Monkey Eyes By Wang, Rong-Fang; Podos, Steven M.; Serle, Janet B.; Baltatu, Ovidiu C. From Current Eye Research (2011), 36(1), 41-46.